Trial
NCT06613516
Effect of Capivasertib on ctDNA in ER Positive Breast Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Imperial College London
Collaborators
AstraZeneca; Sharp; Natera, Inc.
Condition
Breast Cancer
Intervention
Capivasertib
Why stopped
Study was stopped because funder pulled funding for the study. 2 patients were screened however none of the screen patients were eventually recruited
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-24